Colorectal Carcinoma Clinical Trial
Official title:
Use of Text Messages to Increase Whole Grain Consumption in Colorectal Cancer
This clinical trial evaluates whether an adaptive text-message intervention is useful in helping survivors of colorectal cancers (CRC) eat more whole grain foods and less refined grain foods. Most CRC survivors don't achieve the recommended intakes of whole grains or fiber, even though there is strong evidence that a high-fiber diet rich in whole grains lowers the risk of death from CRC. Dietary interventions are a promising approach for reducing death from CRC, and text message interventions specifically are a promising tool for reaching diverse populations. This trial evaluates a text-message based dietary intervention that continuously adapts message content to be specifically tailored for the participant for increasing whole grain consumption.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | November 30, 2024 |
Est. primary completion date | November 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age > 18 years. 2. Subject has provided informed consent. 3. Diagnosis of colon or rectal adenocarcinoma. 4. Not on active treatment at the time of screening and not expected to receive active anticancer therapy (e.g., surgery, radiation, chemotherapy) during the study period. 5. At least 6 weeks since a major surgery and fully recovered. 6. Owns a mobile phone and is willing and able to receive and send text messages. 7. Able to speak/read English or Spanish. 8. Based on a screening survey, eat grains and =<50% of total grains are whole grains. Exclusion Criteria: 1. Does not meet any of the above inclusion criteria. |
Country | Name | City | State |
---|---|---|---|
United States | University of California, San Francisco | San Francisco | California |
United States | Zuckerberg San Francisco General | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Median response rate to text messages | Participants' responses to text messages that ask for a response will be quantified using medians and interquartile range (IQR). The intervention will be determined feasible if the median response proportion to text messages that ask for a reply is >= 70%. | Up to 12 weeks | |
Primary | Overall median score on the System Usability Scale (SUS) | The system usability is comprised of 10 questions assessing participants perceived usability of the intervention. Each item is scored on a scale of 1 (strongly disagree) to 5 ( strongly agree). The SUS yields a single number representing a composite measure of the overall usability of the text messaging system. To calculate the SUS score, Each item's score contribution will ultimately range from 0 to 4 (For items 1,3,5,7,and 9 the score contribution is the item score minus 1 and for items 2,4,6,8 and 10, the contribution is the item score minus 5). The sum of the scores are then multiplied by 2.5 to obtain the overall value. SUS scores have a range of 0 to 100 with a score > 68 indicating above average usability. | At 12 weeks | |
Primary | Overall score on the Acceptability of Intervention Measure (AIM) | The AIM is a four-item measure of implementation that assesses participants perceived acceptability of the intervention. Each item response falls on a scale of 1 (Completely disagree) to 5 (Completely agree). A scaled score is calculated by averaging responses. Scale values range from 1 to 5. The intervention will be determined acceptable if the overall median score is >= 4. | At 12 weeks | |
Primary | Overall score on the Intervention Appropriateness Measure (IAM) | The IAM is a four-item measure of implementation that assesses participants perceived appropriateness of the intervention. Each item response falls on a scale of 1 (Completely disagree) to 5 (Completely agree). A scaled score is calculated by averaging responses. Scale values range from 1 to 5. The intervention will be determined acceptable if the overall median score is >= 4. | At 12 weeks | |
Primary | Feasibility of Intervention Measure (FIM) | The FIM is a four-item measure of implementation that assesses participants perceived appropriateness of the intervention. Each item response falls on a scale of 1 (Completely disagree) to 5 (Completely agree). A scaled score is calculated by averaging responses. Scale values range from 1 to 5. The intervention will be determined acceptable if the overall median score is >= 4. | At 12 weeks | |
Secondary | Change in percent of grains that are whole reported on the Food Frequency Questionnaire (FFQ) | The FFQ will ask about diet in the past 3 months. For each item, participants will be asked to report how often, on average, they ate the specified portion size in the past 3 months. Participants can choose from frequency options ranging from never or less than once per month to >=6 times a day. To compute calorie and nutrient intakes, multiply the frequency of consumption of each food by the amount of each nutrient in the specified portion size using composition values from the U.S. Department of Agriculture and other sources. Percent of grains that are whole = servings per day of whole grains/(servings per day of refined grains + servings per day of whole grains) will be reported over time | Up to 12 weeks | |
Secondary | Change in mean total daily fiber intake (g/d) reported on the Food Frequency Questionnaire (FFQ) | The FFQ will ask about diet in the past 3 months. For each item, participants will be asked to report how often, on average, they ate the specified portion size in the past 3 months. Participants can choose from frequency options ranging from never or less than once per month to >=6 times a day. To compute calorie and nutrient intakes, multiply the frequency of consumption of each food by the amount of each nutrient in the specified portion size using composition values from the U.S. Department of Agriculture and other sources. The mean total daily fiber intake and 95% confidence intervals will be reported over time. | Up to 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04444232 -
Cancer Communication Within Hispanic Social Networks
|
N/A | |
Recruiting |
NCT06233253 -
Online Mindfulness-Based Intervention to Decrease Pre-Procedural Anxiety Before a First-Time Screening Colonoscopy
|
N/A | |
Recruiting |
NCT05799820 -
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
|
Phase 2 | |
Recruiting |
NCT04666727 -
Role of Diet on the Microbiome of the Digestive System
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Recruiting |
NCT02376452 -
Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients
|
Phase 2 | |
Completed |
NCT02254486 -
Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults
|
Phase 3 | |
Completed |
NCT01486251 -
Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer
|
N/A | |
Terminated |
NCT01233544 -
Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases
|
Phase 3 | |
Recruiting |
NCT02073500 -
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
|
||
Completed |
NCT00704600 -
Nelfinavir, a Phase I/Phase II Rectal Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00485316 -
Laparoscopic Assisted Versus Open Resection for Colorectal Carcinoma
|
Phase 3 | |
Recruiting |
NCT04430738 -
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
|
Phase 1/Phase 2 | |
Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
Completed |
NCT05022511 -
Three Birds With One Stone
|
N/A | |
Completed |
NCT04607291 -
Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening
|
Phase 1 | |
Not yet recruiting |
NCT03969784 -
Microparticles in Peritoneal Carcinomatosis of Colorectal Origin
|
N/A | |
Not yet recruiting |
NCT05630794 -
Testing ONC201 to Prevent Colorectal Cancer
|
Phase 1 | |
Terminated |
NCT05291988 -
A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural Communities, The Screen to Save Trial
|
N/A | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 |